Ensoma Closes Series B Extension, Bringing Total Round to $135 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- US stock index futures slip as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Gilead Sciences (GILD) cell therapy unit can grow to multi-billion dollar business by end of 2023 - BMO Capital
May 16, 2023 9:22 AM EDTBMO Capital's Evan David Seigerman upgraded Gilead Sciences (NASDAQ: GILD) to Outperform from Market Perform, raising the price target to $100 per share from $90 in a note Tuesday.
The analyst pointed to three key factors for the upgrade, which were the company's best-in-class cell... More
